Achilles Therapeutics has torn up its strategy. The British biotech is stopping work on its clinical-phase cell therapy, ...

Vanda Pharmaceuticals has failed to persuade the FDA to approve its gastroparesis candidate on the strength of a phase 3 ...

GC Therapeutics has entered gameplay with the mission of unlocking a new generation of cell therapies, uploading with $75 ...

The fall flurry of biotech IPOs shows no signs of abating, with Upstream Bio becoming the latest company to express an ...

Medtronic is offering a peek into its ongoing, at-home trial of people with Parkinson’s disease being treated with adaptive ...

With COVID-19 still spreading and mpox emerging as a public health emergency of international concern, the National ...

GE HealthCare’s recently acquired MIM Software division has secured an FDA clearance for a tool to help quantify the density ...

Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to ...

Having already scooped up the U.S. rights to Capricor Therapeutics’ late-stage Duchenne muscular dystrophy (DMD) therapy, ...

After pushing back the decision date for Applied Therapeutics’ metabolic disorder drug govorestat, the FDA has now decided ...

Innovent Biologics has made the case that its checkpoint inhibitor-cytokine fusion protein has a future in colorectal cancer.

Much of the brain is made up of a constellation of star-shaped cells called astrocytes, which play vital roles in immunity, ...